The global Targeted Protein Degradation Market is emerging as an important area of innovation in drug discovery and therapeutic development. Unlike conventional medicines that primarily work by inhibiting the activity of disease-associated proteins, targeted protein degradation (TPD) technologies are designed to selectively remove unwanted proteins from cells by using the body’s natural protein disposal mechanisms.
The technology landscape includes Proteolysis Targeting Chimeras (PROTACs), molecular glues, Lysosome Targeting Chimeras (LYTACs), and other emerging degradation approaches. These technologies are attracting significant attention because they may provide opportunities to address proteins and biological targets that have historically been difficult to treat using conventional drug-development approaches.
According to Kings Research, the global targeted protein degradation market was valued at USD 447.9 million in 2023 and is projected to grow from USD 532.8 million in 2024 to USD 1,808.3 million by 2031, registering a CAGR of 19.07% during the forecast period. Rising chronic disease prevalence, increasing pharmaceutical R&D investment, advancements in protein degradation technologies, and growing interest in previously difficult-to-drug targets are supporting this rapid expansion.
Rising Prevalence of Chronic Diseases Supports Market Growth
The increasing global burden of chronic diseases is one of the major factors driving investment in new therapeutic technologies. Cancer, neurological disorders, cardiovascular conditions, metabolic diseases, and immune-related disorders continue to create significant demand for more effective treatment approaches.
Traditional drug-development strategies may not be suitable for every disease-associated protein. Some proteins lack conventional binding pockets or have biological characteristics that make them difficult to inhibit effectively. Targeted protein degradation offers a different strategy by eliminating the unwanted protein rather than simply blocking its activity.
Kings Research identifies the growing prevalence of chronic diseases as a key market driver. In the United States alone, the CDC reported in February 2024 that approximately 129 million people were living with at least one major chronic disease, including conditions such as heart disease, cancer, diabetes, obesity, and hypertension.
As the need for innovative medicines increases, pharmaceutical and biotechnology companies are expected to continue investing in technologies capable of expanding the range of therapeutic targets.
PROTAC Technology Expands the Drug Discovery Landscape
PROTACs are among the most widely recognized technologies within the targeted protein degradation field. A PROTAC molecule is generally designed to bring a target protein into proximity with an E3 ubiquitin ligase, triggering a biological process that ultimately marks the target protein for degradation by the proteasome.
This mechanism differs from conventional inhibition because a degrader can potentially remove the target protein from the cell rather than continuously occupying a binding site.
The approach has attracted significant pharmaceutical and biotechnology interest because it could enable the development of medicines against targets that have historically been considered difficult or “undruggable.”
The expanding pipeline of investigational degraders is encouraging companies to improve degrader design, selectivity, potency, pharmacokinetic characteristics, and safety profiles. These advances are expected to strengthen the role of PROTAC technologies in future drug discovery programs.
Molecular Glues Create New Therapeutic Opportunities
Molecular glues represent another important technology within the Targeted Protein Degradation Market. Unlike traditional PROTACs, molecular glues are generally smaller molecules that can promote interactions between proteins and cellular degradation machinery without requiring the same type of bifunctional structure.
According to Kings Research, the molecular glues segment generated USD 159.1 million in revenue in 2023. Their ability to target previously difficult-to-drug proteins using relatively simplified chemical structures is contributing to growing research interest.
The potential of molecular glues extends across oncology, immunology, and neurological diseases. Researchers are continuing to investigate new biological mechanisms and chemical structures that could improve selectivity and therapeutic performance.
The growing number of collaborations focused on molecular glue discovery also demonstrates the industry’s interest in expanding this technology beyond early-stage research.
Drug Discovery Represents a Major Application
The market is segmented by application into drug discovery and therapy development. Drug discovery represented the leading application in 2023, accounting for 62.15% of the market.
Kings Research projects the drug discovery segment to reach USD 1,113.0 million by 2031. The segment is benefiting from increasing investment in early-stage research and the incorporation of TPD technologies into preclinical drug-development pipelines.
Targeted protein degradation platforms can be used during several stages of drug research, including target validation, compound screening, degrader optimization, and biological mechanism studies.
The ability to explore new targets is particularly valuable for pharmaceutical companies seeking differentiated drug candidates. As researchers gain a deeper understanding of protein biology and cellular degradation pathways, TPD platforms are expected to become increasingly integrated into drug-discovery workflows.
AI Accelerates Targeted Protein Degrader Development
Artificial intelligence is becoming an important supporting technology for the targeted protein degradation industry. Drug development involves analyzing large amounts of biological, chemical, structural, and clinical information, making it well suited to computational methods.
AI and machine learning can help researchers identify potential protein interactions, analyze molecular structures, predict biological activity, prioritize compounds, and optimize candidate molecules.
Kings Research identifies the integration of AI in drug development as a major market trend. In February 2025, the Institut Pasteur and Argobio launched Enodia Therapeutics, a French biotechnology company developing treatments for cancer, inflammatory diseases, and viral infections. The company uses generative AI to design selective inhibitors targeting the Sec61/translocon molecular complex.
As AI technologies become more sophisticated, their integration with computational chemistry and biological datasets could accelerate the identification and optimization of new protein degraders.
Strategic Partnerships Strengthen the Industry
Collaboration between pharmaceutical companies, biotechnology firms, academic institutions, and research organizations is playing a major role in advancing targeted protein degradation.
The complexity of degrader discovery often requires expertise spanning medicinal chemistry, molecular biology, structural biology, pharmacology, and clinical development. Partnerships allow organizations to combine complementary capabilities while distributing research and development costs.
For example, in October 2024, Biogen and Neomorph entered a research collaboration to develop molecular glue degraders targeting Alzheimer’s disease, rare neurological diseases, and immunological disorders. The collaboration combines Neomorph’s molecular glue discovery platform with Biogen’s drug-development expertise.
Similarly, in March 2024, C4 Therapeutics entered a collaboration and license agreement with Merck KGaA covering two targeted protein degraders from C4T’s internal discovery pipeline. The agreement included a USD 16 million upfront payment and potential milestone payments of up to USD 740 million.
These collaborations highlight the growing commercial value associated with promising TPD platforms and therapeutic candidates.
Pharmaceutical and Biotechnology Companies Drive Commercialization
The end-use segment includes pharmaceutical and biotechnology companies, academic and research institutes, hospital and clinical laboratories, and other organizations.
Pharmaceutical and biotechnology companies are expected to remain the largest commercial users of targeted protein degradation technologies. Kings Research projects this segment to reach USD 642.9 million by 2031, supported by strategic collaborations and an expanding pipeline of TPD-based therapeutics.
Large pharmaceutical companies have strong incentives to explore TPD because successful degraders could provide differentiated approaches for diseases where conventional treatments have limitations.
Biotechnology companies also play an important role by developing specialized degradation platforms and advancing early-stage candidates. Many smaller companies focus on specific mechanisms or therapeutic areas before partnering with larger pharmaceutical organizations for clinical development and commercialization.
This ecosystem is likely to remain an important feature of the market as new technologies move from discovery toward clinical development.
Neurodegenerative Diseases and Oncology Offer Significant Potential
Cancer represents an important area of research for targeted protein degradation because many tumors depend on specific proteins or signaling pathways for growth and survival.
TPD technologies may enable researchers to selectively eliminate proteins associated with cancer progression, potentially opening new therapeutic strategies for difficult-to-treat cancers.
Neurological diseases are another promising area. Developing therapies for conditions such as Alzheimer’s and Huntington’s diseases is particularly challenging because of complex disease mechanisms and the involvement of protein aggregation.
The emergence of specialized technologies such as TRIMTAC demonstrates how researchers are exploring new degradation mechanisms for neurological disorders. In March 2025, Cambridge Innovation Capital co-led a USD 31 million seed financing round for TRIMTECH Therapeutics, which is developing TPD therapies for neurodegenerative diseases using its proprietary TRIMTAC technology.
Continued investment across oncology, neuroscience, immunology, and other therapeutic areas is expected to broaden the addressable market.
Clinical Development Remains a Major Challenge
Despite strong scientific potential, targeted protein degradation faces several development challenges. One of the most important is the long timeline and high cost of clinical development.
Novel degraders may require extensive preclinical testing, specialized assays, detailed pharmacological evaluation, and carefully designed clinical trials. Researchers must demonstrate not only that a molecule can degrade its intended target but also that the degradation produces meaningful therapeutic benefits without unacceptable safety risks.
The complexity of these development programs can increase financial risk, particularly for smaller biotechnology companies with limited resources.
Kings Research identifies extended clinical development timelines as a major market challenge. Strategic partnerships, licensing agreements, and public-private collaborations can help companies share costs, access specialized expertise, and accelerate progression from discovery to clinical development.
North America Currently Leads the Market
North America represented the leading regional market for targeted protein degradation in 2023. The region accounted for approximately 33.24% of the global market, with a valuation of USD 148.9 million.
The region benefits from established pharmaceutical and biotechnology industries, leading research institutions, strong venture investment, and advanced drug-development infrastructure.
The United States is particularly important because of its extensive biotechnology ecosystem and regulatory framework. The U.S. Food and Drug Administration provides established pathways for the development of novel therapeutic products, including investigational new drug and marketing-approval processes.
In February 2024, Arvinas and Pfizer received FDA Fast Track designation for vepdegestrant (ARV-471) as a monotherapy for adults with ER+/HER2- locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. Vepdegestrant is an investigational oral PROTAC protein degrader targeting the estrogen receptor.
Such developments demonstrate the increasing transition of TPD technologies from laboratory research toward clinical applications.
Asia Pacific Emerges as a High-Growth Region
Asia Pacific is expected to experience the fastest growth in the global Targeted Protein Degradation Market. Kings Research projects the regional market to expand at a CAGR of 20.18% from 2024 to 2031, reaching approximately USD 421.3 million by 2031.
Growing healthcare expenditure, expanding biotechnology industries, increasing pharmaceutical R&D activity, and government support for biopharmaceutical innovation are contributing to regional development.
China, Japan, South Korea, and India are strengthening their research capabilities and clinical development infrastructure. Academic institutions are also increasing their involvement in protein degradation research through domestic and international collaborations.
As the region develops a stronger biotechnology ecosystem, Asia Pacific could become increasingly important for TPD research, clinical trials, technology licensing, and pharmaceutical commercialization.
Regulatory Frameworks Influence Market Development
Targeted protein degradation therapies must satisfy regulatory requirements governing new medicines and clinical research.
In the United States, the Food and Drug Administration (FDA) oversees the development and approval of TPD therapies. Developers generally need to submit an Investigational New Drug application before beginning human clinical trials, followed by an appropriate marketing application for products that demonstrate safety and efficacy.
In India, the Central Drugs Standard Control Organization (CDSCO) regulates new drug development. Targeted protein degradation therapies are subject to India’s New Drugs and Clinical Trials Rules, 2019, which establish requirements for investigational drugs and clinical trials.
As TPD therapies progress toward commercialization, regulatory agencies will play an important role in evaluating their safety, efficacy, manufacturing quality, and clinical benefits.
Competitive Landscape and Industry Developments
The Targeted Protein Degradation Market includes established pharmaceutical companies, biotechnology firms, research organizations, and specialized technology developers.
Key companies identified by Kings Research include Hybrigenics Services, Foghorn Therapeutics, LifeSensors, Thermo Fisher Scientific, C4 Therapeutics, Evotec, Proxygen, Arvinas, Merck KGaA, Nurix Therapeutics, Bayer, Kymera Therapeutics, Bio-Techne, Zymeworks, and Ambagon.
Competition is increasingly focused on developing proprietary degradation technologies, expanding therapeutic pipelines, identifying new protein targets, and establishing partnerships with pharmaceutical companies.
Companies are also using licensing agreements and milestone-based collaborations to finance development while expanding access to global commercialization capabilities. This business model is particularly valuable in a field where discovery and clinical development require substantial specialized resources.
Future Outlook of the Targeted Protein Degradation Market
The future of the Targeted Protein Degradation Market is expected to be shaped by advances in molecular biology, AI-assisted drug discovery, medicinal chemistry, protein engineering, and precision medicine.
PROTACs and molecular glues are likely to remain important technologies, while emerging approaches such as LYTACs and other degradation mechanisms could expand the range of proteins that can be targeted.
The integration of AI may further accelerate discovery by helping researchers evaluate molecular interactions, identify promising compounds, and optimize degrader characteristics. Increasing computational capabilities could also reduce the time required to move promising candidates from early research into development.
At the therapeutic level, oncology, neurodegenerative diseases, inflammatory disorders, and other chronic conditions are expected to remain major areas of research.
As more TPD candidates advance through clinical development, successful clinical outcomes could increase confidence in the technology and encourage additional pharmaceutical investment.
Conclusion
The Targeted Protein Degradation Market is emerging as a promising frontier in modern drug discovery, offering a fundamentally different strategy for addressing disease-associated proteins. According to Kings Research, the market is projected to grow from USD 532.8 million in 2024 to USD 1,808.3 million by 2031, representing a strong CAGR of 19.07%.
The growing prevalence of chronic diseases, increasing pharmaceutical R&D investment, demand for treatments against difficult-to-drug targets, and advances in PROTACs, molecular glues, LYTACs, and AI-assisted drug development are creating significant opportunities.
North America currently leads the market, while Asia Pacific is expected to experience the fastest growth. Drug discovery remains the dominant application, and pharmaceutical and biotechnology companies are expected to remain central to commercialization.
At the same time, high development costs, extended clinical timelines, regulatory requirements, and the complexity of translating promising laboratory findings into safe and effective therapies will remain important challenges.
As researchers continue to uncover new ways of selectively eliminating disease-causing proteins, targeted protein degradation has the potential to expand the boundaries of drug discovery and contribute to the development of next-generation precision therapies.
